{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:16:08Z","timestamp":1788869768933,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13821-6","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:56:11Z","timestamp":1782208571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting\u2013based retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4877-2052","authenticated-orcid":false,"given":"Yang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-5001","authenticated-orcid":false,"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"13821_CR1","doi-asserted-by":"crossref","unstructured":"Reghukumar A. Drivers of antimicrobial resistance [M]. Handbook on antimicrobial resistance. 2023: 585\u2013600.","DOI":"10.1007\/978-981-19-9279-7_27"},{"key":"13821_CR2","doi-asserted-by":"publisher","first-page":"154352","DOI":"10.1016\/j.jcrc.2023.154352","volume":"77","author":"M Leone","year":"2023","unstructured":"Leone M, Duclos G, Lakbar I, Martin-Loeches I, Einav S. Antimicrobial resistance and outcome in the critically ill patient: An opinion paper [J]. J Crit Care. 2023;77:154352.","journal-title":"J Crit Care"},{"key":"13821_CR3","doi-asserted-by":"crossref","unstructured":"Palmore TN, Henderson DK. Controlling the spread of resistant pathogens in the intensive care unit [M]. Antimicrob Drug Resist. 2017:1551\u201364.","DOI":"10.1007\/978-3-319-47266-9_41"},{"key":"13821_CR4","unstructured":"World Health O. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis [R]. World Health Organization. 2017."},{"issue":"6","key":"13821_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cmi.2025.02.018","volume":"31","author":"S Karakonstantis","year":"2025","unstructured":"Karakonstantis S, Kritsotakis EI, Tziolos RN, et al. Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patients [J]. Clin Microbiol Infect. 2025;31(6):1033\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"13821_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13756-019-0590-7","volume":"8","author":"X Zhen","year":"2019","unstructured":"Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review [J]. Antimicrob Resist Infect Control. 2019;8:137.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"Suppl 1","key":"13821_CR7","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/cid\/ciaa1581","volume":"72","author":"RE Nelson","year":"2021","unstructured":"Nelson RE, Hatfield KM, Wolford H, et al. National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States [J]. Clin Infect Dis. 2021;72(Suppl 1):S17\u201326.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"13821_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J. Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet? [J]. Int J Antimicrob Agents. 2016;48(6):592\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"13821_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","volume":"72","author":"J Koch-Weser","year":"1970","unstructured":"Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy [J]. Ann Intern Med. 1970;72(6):857\u201368.","journal-title":"Ann Intern Med"},{"issue":"1","key":"13821_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) [J]. Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"13821_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1586\/14787210.5.5.811","volume":"5","author":"A Kwa","year":"2007","unstructured":"Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E) [J]. Expert Rev Anti Infect Ther. 2007;5(5):811\u201321.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"13821_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bcp.15061","volume":"88","author":"L Han","year":"2022","unstructured":"Han L, Xu FM, Zhang XS, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity [J]. Br J Clin Pharmacol. 2022;88(3):1202\u201310.","journal-title":"Br J Clin Pharmacol"},{"key":"13821_CR13","doi-asserted-by":"publisher","first-page":"1466888","DOI":"10.3389\/fphar.2024.1466888","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang C, Chen J, et al. Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study [J]. Front Pharmacol. 2024;15:1466888.","journal-title":"Front Pharmacol"},{"issue":"04","key":"13821_CR14","first-page":"292","volume":"44","author":"Chinese Society of Infectious Diseases of China Medical Education Association, Chinese Thoracic Society of Chinese Medical Association, Chinese Society of Critical Care Medicine of Chinese Medical Association, Chinese Society of Hematology of Chinese Medical Association, Chinese Society for Bacterial Infections and Antimicrobial Resistance Prevention and Control of Chinese Medical Association","year":"2021","unstructured":"Chinese Society of Infectious Diseases of China Medical Education Association, Chinese Thoracic Society of Chinese Medical Association, Chinese Society of Critical Care Medicine of Chinese Medical Association, Chinese Society of Hematology of Chinese Medical Association, Chinese Society for Bacterial Infections and Antimicrobial Resistance Prevention and Control of Chinese Medical Association. Professional Committee for Clinical Evaluation and Research of Drugs of Chinese Pharmaceutical Association, Global Chinese Society for Clinical Microbiology and Infection. Multidisciplinary Expert Consensus on Rational Clinical Application of Polymyxins in China [J]. Chin J Tuberculosis Respiratory Dis. 2021;44(04):292\u2013310.","journal-title":"Chin J Tuberculosis Respiratory Dis"},{"issue":"09","key":"13821_CR15","first-page":"844","volume":"30","author":"Writing Group of","year":"2014","unstructured":"Writing Group of. Technical Guidelines for Clinical Trials of Antibacterial Drugs [J]. Chin J Clin Pharmacol. 2014;30(09):844\u201356.","journal-title":"Chin J Clin Pharmacol"},{"key":"13821_CR16","doi-asserted-by":"crossref","unstructured":"KDIGO. 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int. 2024;105(4s): S117-s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"1","key":"13821_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) [J]. Crit Care. 2013;17(1):204.","journal-title":"Crit Care"},{"issue":"4","key":"13821_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/flgastro-2021-101886","volume":"13","author":"PN Brennan","year":"2022","unstructured":"Brennan PN, Cartlidge P, Manship T, Dillon JF. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI) [J]. Frontline Gastroenterol. 2022;13(4):332\u20136.","journal-title":"Frontline Gastroenterol"},{"key":"13821_CR19","doi-asserted-by":"publisher","first-page":"1540925","DOI":"10.3389\/fphar.2025.1540925","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu H, Tang L, Zheng L, et al. Colistin sulfate versus polymyxin B for the treatment of infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter retrospective cohort study [J]. Front Pharmacol. 2025;16:1540925.","journal-title":"Front Pharmacol"},{"issue":"1","key":"13821_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12879-025-10773-1","volume":"25","author":"W Bu","year":"2025","unstructured":"Bu W, Wang C, Wu Y, et al. Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study [J]. BMC Infect Dis. 2025;25(1):390.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"13821_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3855\/jidc.18887","volume":"18","author":"D Liu","year":"2024","unstructured":"Liu D, Jie F, Ding Y, Qu H, Chen D, Huang J. Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB [J]. J Infect Dev Ctries. 2024;18(7):1050\u20137.","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"13821_CR22","doi-asserted-by":"publisher","first-page":"107031","DOI":"10.1016\/j.ijantimicag.2023.107031","volume":"63","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Dong R, Huang Y, Ling X, Ye Z, Jiang S. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study [J]. Int J Antimicrob Agents. 2024;63(1):107031.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"13821_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/phar.4601","volume":"44","author":"QJ Yang","year":"2024","unstructured":"Yang QJ, Xiang BX, Song MH, Yang CY, Liang JH, Xie YL, Zuo XC. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study [J]. Pharmacotherapy. 2024;44(8):631\u201341.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"13821_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12879-023-08339-0","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang J, Shah BK, Zhao J, Xiong J, Wang C, Xie S. Comparative study of polymyxin B and colistin sulfate in the treatment of severe comorbid patients infected with CR-GNB [J]. BMC Infect Dis. 2023;23(1):351.","journal-title":"BMC Infect Dis"},{"key":"13821_CR25","doi-asserted-by":"crossref","unstructured":"Qin Y, Ding Q, Huang S, et al. Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis [J]. Int J Clin Pharm. 2025.","DOI":"10.1007\/s11096-025-02036-5"},{"issue":"1","key":"13821_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s15010-024-02324-8","volume":"53","author":"HH Zhuang","year":"2025","unstructured":"Zhuang HH, Qu Q, Long WM, et al. Ceftazidime\/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study [J]. Infection. 2025;53(1):95\u2013106.","journal-title":"Infection"},{"key":"13821_CR27","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.2147\/IDR.S473200","volume":"17","author":"YC Ma","year":"2024","unstructured":"Ma YC, Sun YQ, Wu X, Wang YJ, Yang XL, Gu JJ. Clinical Effectiveness and Safety of Colistin Sulphate in Treating Infections Caused by Carbapenem-Resistant Organisms and Analysis of Influencing Factors [J]. Infect Drug Resist. 2024;17:3793\u2013804.","journal-title":"Infect Drug Resist"},{"key":"13821_CR28","doi-asserted-by":"crossref","unstructured":"Stamatiou R, Vasilaki A, Tzini D, et al. Critical-illness: combined effects of colistin and vasoactive drugs: a pilot study [J]. Antibiot (Basel). 2023;12(6).","DOI":"10.3390\/antibiotics12061057"},{"issue":"44","key":"13821_CR29","doi-asserted-by":"publisher","first-page":"e45746","DOI":"10.1097\/MD.0000000000045746","volume":"104","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Shen Y, Liu Z, Zhang S, Jin W, Li Z. Association between vasoactive drug use and 28-day in-hospital mortality in patients with septic shock in the intensive care unit: A retrospective study based on the MIMIC-IV database [J]. Med (Baltim). 2025;104(44):e45746.","journal-title":"Med (Baltim)"},{"issue":"1","key":"13821_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-022-03947-9","volume":"26","author":"SH Wang","year":"2022","unstructured":"Wang SH, Yang KY, Sheu CC, Chen WC, Chan MC, Feng JY, et al. The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study [J]. Crit Care. 2022;26(1):91.","journal-title":"Crit Care"},{"issue":"13","key":"13821_CR31","doi-asserted-by":"publisher","first-page":"e33735","DOI":"10.1016\/j.heliyon.2024.e33735","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhang J, Yang P, Wang R, Chen T, Li L. The role of polymyxin B-immobilized hemoperfusion in reducing mortality and enhancing hemodynamics in patients with sepsis and septic shock: A systematic review and meta-analysis [J]. Heliyon. 2024;10(13):e33735.","journal-title":"Heliyon"},{"issue":"1","key":"13821_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365548.2013.844350","volume":"46","author":"R Crusio","year":"2014","unstructured":"Crusio R, Rao S, Changawala N, Paul V, Tiu C, van Ginkel J, et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy [J]. Scand J Infect Dis. 2014;46(1):1\u20138.","journal-title":"Scand J Infect Dis"},{"key":"13821_CR33","doi-asserted-by":"crossref","unstructured":"Pu N, Li K. Risk factors, prognostic impact, and antimicrobial susceptibility profiles of carbapenem-resistant Acinetobacter baumannii bloodstream infections: a retrospective cohort study [J]. Sci Rep. 2026.","DOI":"10.1038\/s41598-026-47397-7"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13821-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:03:33Z","timestamp":1788869013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13821-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13821"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13821-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. It is a retrospective study based on anonymous patient data. Ethical approval for the present research was granted by the Medical Ethics Committee of the First People\u2019s Hospital of Changzhou City (approval number: (2026) Sect.\u00a077). The waiver of informed consent was also approved by the aforementioned identical ethics committee owing to the retrospective design and adoption of fully anonymized clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1613"}}